SCHEMBL20129178

SCHEMBL20129178

CCC1(COCCCOC2CN(C(=O)OC(C)(C)C)C2)COC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.37
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RECQL P46063 1/20 0.35
PRMT5 O14744 2/20 0.34
WDR77 Q9BQA1 2/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
PDE4B Q07343 3/20 0.32
PDE4A P27815 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
HPGD P15428 1/20 0.32
RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129177 0.91 NR1H2 (0.40) NR1H2USP2SMN1; SMN2RECQLPRMT5
SCHEMBL20133230 0.86 NR1H2 (0.36) NR1H2USP2SMN1; SMN2RECQLPRMT5
SCHEMBL20233783 0.86 NR1H2 (0.34) NR1H2USP2SMN1; SMN2RECQLPRMT5
SCHEMBL20129034 0.80 NR1H2 (0.43) NR1H2USP2SMN1; SMN2PRMT5WDR77
SCHEMBL27097799 0.80 NR1H2 (0.43) NR1H2USP2SMN1; SMN2PRMT5WDR77
SCHEMBL20129207 0.80 NR1H2 (0.43) NR1H2USP2SMN1; SMN2RECQLPRMT5
SCHEMBL20129252 0.80 NR1H2 (0.43) NR1H2USP2SMN1; SMN2RECQLPRMT5
SCHEMBL20129035 0.78 NR1H2 (0.47) NR1H2USP2SMN1; SMN2RECQLPRMT5
SCHEMBL20129254 0.78 NR1H2 (0.47) NR1H2USP2SMN1; SMN2RECQLPRMT5
SCHEMBL20129179 0.77 NR1H2 (0.48) NR1H2USP2SMN1; SMN2PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN NR1H2 3409/4885USP2 80/4885SMN1; SMN2 1058/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 NR1H2 3751/4885USP2 52/4885SMN1; SMN2 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.